High‐Yield Production of Extracellular Vesicle Subpopulations with Constant Quality Using Batch‐Refeed Cultures
Source abstract
Abstract
Abstract The conventional manufacturing of extracellular vesicles (EVs) is characterized by low yields and batch‐to‐batch variability, hampering fundamental research on EVs and their practical applications. Perfusion operations have huge potential to address these limitations and increase the productivity and quality of EVs. In this study, perfusion cultures are simulated with batch‐refeed systems and their productivity is compared with that achieved using batch cultures. It is shown that a shift from batch to batch‐refeed system can increase the space‐time yields of a target EV subpopulation characterized by CD81 and CD63 biomarkers by threefold. Moreover, it is demonstrated that the method facilitates the consistent production of the target EVs from cells maintained under constant conditions for 13 days. These results indicate that the use of perfusion cultures is a promising strategy to increase the manufacturing yield of EVs and control the production of specific EV subpopulations with constant quality attributes, thereby improving reproducibility.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Cell Adhesion Molecules Research · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry and Applied Biosciences Institute for Chemical and Bioengineering ETH Zurich Vladimir‐Prelog‐Weg 1–5/10 Zurich 8093 Switzerland
References (55)
Show source-provided references
1. 10.1038/d41573-020-00220-y10.1038/d41573-020-00220-y ↗
2. 10.1002/biot.20180052810.1002/biot.201800528 ↗
3. 10.1016/j.molmed.2018.01.00610.1016/j.molmed.2018.01.006 ↗
4. 10.1038/s42003-020-01277-610.1038/s42003-020-01277-6 ↗
5. 10.3389/fbioe.2021.80861410.3389/fbioe.2021.808614 ↗
6. 10.1016/j.scr.2020.10197810.1016/j.scr.2020.101978 ↗
7. 10.1038/s41565-021-00931-210.1038/s41565-021-00931-2 ↗
8. 10.1016/j.addr.2021.11384310.1016/j.addr.2021.113843 ↗
9. 10.3389/fphar.2021.67015810.3389/fphar.2021.670158 ↗
10. 10.1080/07388551.2020.180540610.1080/07388551.2020.1805406 ↗
11. 10.1002/adhm.20210165810.1002/adhm.202101658 ↗
12. 10.1002/advs.20200259610.1002/advs.202002596 ↗
13. 10.1186/1471-2407-12-42110.1186/1471-2407-12-421 ↗
14. 10.1016/j.isci.2019.05.02910.1016/j.isci.2019.05.029 ↗
15. 10.1080/20013078.2018.144013210.1080/20013078.2018.1440132 ↗
16. 10.1002/jev2.1208110.1002/jev2.12081 ↗
17. 10.1039/D0BM01696A10.1039/D0BM01696A ↗
18. 10.3389/fbioe.2022.83674710.3389/fbioe.2022.836747 ↗
19. 10.1016/j.ymthe.2018.09.01510.1016/j.ymthe.2018.09.015 ↗
20. Kang H. · Adv. Healthcare Mater. · 2022 · 11
21. 10.1002/bit.2458410.1002/bit.24584 ↗
22. 10.1002/bit.2552910.1002/bit.25529 ↗
23. 10.1016/j.biotechadv.2018.04.01110.1016/j.biotechadv.2018.04.011 ↗
24. 10.1016/j.copbio.2017.12.01510.1016/j.copbio.2017.12.015 ↗
25. 10.1016/j.tibtech.2013.05.01110.1016/j.tibtech.2013.05.011 ↗
26. 10.3389/fbioe.2020.0061710.3389/fbioe.2020.00617 ↗
27. 10.1186/s13287-021-02190-310.1186/s13287-021-02190-3 ↗
28. 10.1172/jci.insight.9926310.1172/jci.insight.99263 ↗
29. 10.1186/s13287-020-01719-210.1186/s13287-020-01719-2 ↗
30. 10.1007/s10565-019-09504-510.1007/s10565-019-09504-5 ↗
31. 10.1039/D0AN01199A10.1039/D0AN01199A ↗
32. 10.1073/pnas.152123011310.1073/pnas.1521230113 ↗
33. 10.1016/j.cell.2019.02.02910.1016/j.cell.2019.02.029 ↗
34. 10.1002/bit.2699910.1002/bit.26999 ↗
35. 10.3389/fcell.2022.72861610.3389/fcell.2022.728616 ↗
36. Kim J. · Extracell. Vesicles Circ. Nucleic Acids · 2021 · 2 · 3
37. 10.1016/j.jconrel.2016.02.03710.1016/j.jconrel.2016.02.037 ↗
38. 10.1126/sciadv.aaz698010.1126/sciadv.aaz6980 ↗
39. 10.4236/cm.2020.11300710.4236/cm.2020.113007 ↗
40. 10.1002/adhm.20210002110.1002/adhm.202100021 ↗
41. 10.1016/j.jbiotec.2019.12.01710.1016/j.jbiotec.2019.12.017 ↗
42. 10.1007/s00253-015-6855-z10.1007/s00253-015-6855-z ↗
43. 10.1098/rstb.2016.047910.1098/rstb.2016.0479 ↗
44. 10.1002/biot.20170072110.1002/biot.201700721 ↗
45. 10.1002/btpr.279010.1002/btpr.2790 ↗
46. 10.1080/07388551.2021.199882110.1080/07388551.2021.1998821 ↗
47. 10.1016/j.jbiotec.2015.06.42810.1016/j.jbiotec.2015.06.428 ↗
48. 10.1002/elsc.20130001310.1002/elsc.201300013 ↗
49. 10.3389/fnut.2020.57514610.3389/fnut.2020.575146 ↗
50. 10.1007/s00253-017-8531-y10.1007/s00253-017-8531-y ↗
51. 10.1080/20013078.2019.159666910.1080/20013078.2019.1596669 ↗
52. 10.1016/j.tips.2020.12.00410.1016/j.tips.2020.12.004 ↗
53. 10.1016/j.addr.2020.04.00410.1016/j.addr.2020.04.004 ↗
54. 10.1002/smll.20220473610.1002/smll.202204736 ↗
55. 10.1038/nmeth.418510.1038/nmeth.4185 ↗